Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 and QL1706 in Recurrent or Metastatic Cervical Cancer
NCT07542717Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Apr 2026
- Primary completion
- Mar 2028
- Modality
- Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of becotatug vedotin, iparomlimab + tuvonralimab in Cervical Cancer (CC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
becotatug vedotiniparomlimab + tuvonralimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07542717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07542717.